Physician profile
John J Sutton
NPI 1164490025
$7,904.40
in general payments reported to CMS, 2019-2025
29 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $1,189 · 2021: $1,105 · 2022: $845 · 2023: $1,172 · 2024: $1,149 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,228.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $789.91 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $719.17 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $648.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $614.61 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $584.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $550.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $496.45 | 2019-2025 | |
| Amgen INC. | $421.79 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $389.53 | 2019-2025 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $279.58 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $144.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.92 | 2019-2023 | Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $114.62 | 2021-2023 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $101.81 | 2024 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $84.70 | 2020-2021 | |
| Amarin Pharma, INC. | $82.71 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $73.26 | 2025 | Daybue |
| Xeris Pharmaceuticals, INC. | $70.47 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $64.71 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.86 | 2025 | Caplyta |
| Mylan Specialty L.P. | $55.75 | 2020-2022 | |
| Verona Pharma, INC. | $49.44 | 2025 | Ohtuvayre |
| Allergan, INC. | $46.53 | 2019-2020 | |
| Boston Scientific Corporation | $31.26 | 2023-2024 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $23.44 | 2023 | Rexulti, Abilify Maintena |
| Lexicon Pharmaceuticals, INC. | $20.33 | 2023 | Inpefa |
| Abbott Laboratories | $17.10 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $15.66 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.